EP0472663A4 - Method of treatment of hepatitis - Google Patents

Method of treatment of hepatitis

Info

Publication number
EP0472663A4
EP0472663A4 EP19900909416 EP90909416A EP0472663A4 EP 0472663 A4 EP0472663 A4 EP 0472663A4 EP 19900909416 EP19900909416 EP 19900909416 EP 90909416 A EP90909416 A EP 90909416A EP 0472663 A4 EP0472663 A4 EP 0472663A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900909416
Other versions
EP0472663A1 (en
Inventor
Hiroaki Mitsuya
Jay H. Hoofnagle
Samuel Broder
Robert Yarchoan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Commerce
Original Assignee
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Commerce filed Critical US Department of Commerce
Publication of EP0472663A1 publication Critical patent/EP0472663A1/en
Publication of EP0472663A4 publication Critical patent/EP0472663A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
EP19900909416 1989-05-15 1990-05-15 Method of treatment of hepatitis Withdrawn EP0472663A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35150289A 1989-05-15 1989-05-15
US351502 1989-05-15

Publications (2)

Publication Number Publication Date
EP0472663A1 EP0472663A1 (en) 1992-03-04
EP0472663A4 true EP0472663A4 (en) 1992-07-01

Family

ID=23381196

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900909416 Withdrawn EP0472663A4 (en) 1989-05-15 1990-05-15 Method of treatment of hepatitis

Country Status (5)

Country Link
EP (1) EP0472663A4 (en)
JP (1) JPH04501857A (en)
AU (1) AU5832990A (en)
CA (1) CA2054771A1 (en)
WO (1) WO1990014091A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216510A2 (en) * 1985-08-26 1987-04-01 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine
EP0307914A2 (en) * 1987-09-18 1989-03-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing a dideoxynucleoside
EP0302760B1 (en) * 1987-08-07 1992-07-29 The Governors of the University of Alberta Antiviral therapy for hepatitis b using 2',3'-dideoxynucleosides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
US4704357A (en) * 1985-09-30 1987-11-03 United States Of America As Represented By The Department Of Health And Human Services Immortalized T-lymphocyte cell line for testing HTLV-III inactivation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216510A2 (en) * 1985-08-26 1987-04-01 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine
EP0302760B1 (en) * 1987-08-07 1992-07-29 The Governors of the University of Alberta Antiviral therapy for hepatitis b using 2',3'-dideoxynucleosides
EP0307914A2 (en) * 1987-09-18 1989-03-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing a dideoxynucleoside

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 33, no. 3, March 1989, pages 336-339, American Society for Microbiology; B. LEE et al.: "In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus" *
ANTIVIRAL RESEARCH, vol. 12, nos. 5-6, 1989, pages 301-310, Elsevier Science Publishers B.V. (Biomedical Division); B. LÖFGREN et al.: "Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs" *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 156, no. 3, 15th November 1988, pages 1144-1155, Academic Press, Inc.; S. SUZUKI et al.: "Inhibition of duck hepatitis B virus replication by purine 2',3'-dideoxynucleosides" *
GASTROENTEROLOGY, vol. 96, no. 5, part 2, 13th 19th May 1989, page A628, Washington, DC, US; P. MARTIN et al.: "2',3'-Dideoxyinosine(DD1) and dideoxyguanosine (DD3) are potent inhibitors of hepadnaviruses in vivo" *
HEPATOLOGY, vol. 8, no. 5, 1988, page 1329, abstract no. 444; P. MARTIN et al.: "Effects of 2',3'-dideoxyadenosine on duck hepatitis B virus" *
LAB. INVEST., vol. 60, no. 1, January 1989, page 71A, abstract no. 420; K.L. PAUW et al.: "Histological effects of 2',3'-dideoxypurines in duck hepatitis B virus infection" *
See also references of WO9014091A1 *

Also Published As

Publication number Publication date
JPH04501857A (en) 1992-04-02
EP0472663A1 (en) 1992-03-04
WO1990014091A1 (en) 1990-11-29
AU5832990A (en) 1990-12-18
CA2054771A1 (en) 1990-11-16

Similar Documents

Publication Publication Date Title
EP0472595A4 (en) Method of treatment of hepatitis
EP0472663A4 (en) Method of treatment of hepatitis
GB8916394D0 (en) Method of treatment
GB8928896D0 (en) Method of treatment
GB8906428D0 (en) Method of treatment
GB8906425D0 (en) Method of treatment
GB8906424D0 (en) Method of treatment
GB8912934D0 (en) Method of treatment
GB8904258D0 (en) Method of treatment
GB8906426D0 (en) Method of treatment
GB8911258D0 (en) Method of treatment
GB8906427D0 (en) Method of treatment
GB8929033D0 (en) Method of treatment
GB8906429D0 (en) Method of treatment
GB8906430D0 (en) Method of treatment
GB8912935D0 (en) Method of treatment
GB8924155D0 (en) Method of treatment
GB8920985D0 (en) Method of treatment
ZA904464B (en) Method of treatment using 17beta-cyclopropylaminoandrostene
PH27228A (en) Method of treatment using 18-cyano-progesterone derivatives
GB8801688D0 (en) Method of treatment
GB8812232D0 (en) Method of treatment
GB8812224D0 (en) Method of treatment
GB8811891D0 (en) Method of treatment
GB8811006D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920513

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19931201